These advantages have been borne out in the clinic; CDX-3379 has a calculated serum half-life of 17 days, which combined with its potency, ensures prolonged inhibition of HER3 phosphorylation in HNSCC tumors from patients, as demonstrated in a recently completed window-of-opportunity study42. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.